Infliximab in ulcerative colitis
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). I...
Guardado en:
Autores principales: | Avi Levin, Oren Shibolet |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d7d25d975b084e1b95110d58fe7dcd89 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
por: Bradley GM, et al.
Publicado: (2012) -
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
por: Viscido A, et al.
Publicado: (2019) -
Golimumab in unresponsive ulcerative colitis
por: Lippert E, et al.
Publicado: (2014) -
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
por: Gledhill T, et al.
Publicado: (2013) -
Infliximab for the treatment of plaque psoriasis
por: Jennifer S Gall, et al.
Publicado: (2008)